Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Clinical

Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence

Prostate Cancer and Prostatic Diseases (2024)Cite this article

Subjects

Abstract

The systematic review by Saouli et al. investigates the role of radical prostatectomy (RP) in managing oligometastatic prostate cancer (omPCa) [1]. They analyzed the existing literature to assess the oncological and functional outcomes of RP for these patients. RP is feasible and has an acceptable risk of complications. However, the lack of consensus on the definitions of omPCa and the low-quality evidence of the available comparative and retrospective studies, RP in omPCa should not be recommended outside of clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Saouli A, Touzani A, Martini A, Beauval JB, Dergamoun H, Ziouziou I, et al. Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00752-5.

  2. Ravi P, Kwak L, Xie W, Kelleher K, Acosta AM, McKay RR, et al. Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis. J Urol. 2022;208:838–45.

    Article  PubMed  Google Scholar 

  3. Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022;23:304–16.

    Article  CAS  PubMed  Google Scholar 

  4. Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011;29:2040–5.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Bossi A, Foulon S, Maldonado X, Sargos P, McDermott RS, Flechon A, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. J Clin Oncol. 2023;41:LBA5000.

    Article  Google Scholar 

  7. Boevé LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410–8.

    Article  PubMed  Google Scholar 

  8. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023;185:178–215.

    Article  PubMed  Google Scholar 

  9. Conteduca V, Di Tullio P, Allamprese R, Bruno G, Lolli C, Schepisi G, et al. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. Prostate Cancer Prostatic Dis. 2024. https://doi.org/10.1038/s41391-024-00800-8.

  10. Vanden Berg RNW, Zilli T, Achard V, Dorff T, Abern M. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: a review. Prostate Cancer Prostatic Dis. 2023;26:702–11.

    Article  CAS  PubMed  Google Scholar 

  11. Moul JW, Shore ND, Pienta KJ, Czernin J, King MT, Freedland SJ. Application of next-generation imaging in biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00711-0.

  12. Benjamin DJ, Shrestha A, Fellman D, Cress RD, Lythgoe MP, Rezazadeh Kalebasty A. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00732-9.

  13. Daskivich TJ, Naser-Tavakolian A, Gale R, Luu M, Friedrich N, Venkataramana A, et al. Variation in communication of side effects in prostate cancer treatment consultations. Prostate Cancer Prostatic Dis. 2024. https://doi.org/10.1038/s41391-024-00806-2.

  14. Schumacher FA, Helenowski IB, Sun Z, Oswald LB, Gonzalez BD, Moses KA, et al. Treatment decision-making among patients with metastatic prostate cancer: impact of decision locus of control on functional outcomes and decision satisfaction. Prostate Cancer Prostatic Dis. 2023;26:201–6.

    Article  PubMed  Google Scholar 

  15. Shore N, Antonarakis E, Ross A, Marshall C, Stratton K, Ayanambakkam A, et al. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024. https://doi.org/10.1038/s41391-024-00803-5.

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Tanya Dorff

  2. Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India

    Sheetal R. Kashid & Vedang Murthy

  3. Sapienza University, Rome, Italy

    Riccardo Lombardo & Cosimo De Nunzio

Authors
  1. Tanya Dorff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheetal R. Kashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vedang Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riccardo Lombardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cosimo De Nunzio
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TD, SRK, VM, RL, and CDN: conceptualization, writing, analysis, reviewing the final version, and approval of the final version.

Corresponding author

Correspondence to Cosimo De Nunzio.

Ethics declarations

Competing interests

TD is consulting for AstraZeneca, Bayer, Janssen. CDN: Editor in Chief Prostate Cancer and Prostatic Diseases. SRK, VM, and RL: none.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dorff, T., Kashid, S.R., Murthy, V. et al. Prostatectomy in oligometastatic prostate cancer: a call for high-quality evidence. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00838-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41391-024-00838-8

Search

Advanced search

Quick links